Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Equal-Weight on Amdocs, Raises Price Target to $95

Barclays analyst Tavy Rosner maintains Amdocs (NASDAQ:DOX) with a Equal-Weight and raises the price target from $89 to $95.

byBenzinga Newsdesk

August 4, 2022

1 minute read

Barclays analyst Tavy Rosner maintains Amdocs (NASDAQ:DOX) with a Equal-Weight and raises the price target from $89 to $95.

Notable Option Care Health Insider Makes $247.48 Million Sale

By Benzinga Insights

Today, 8:47 PM

Timothy Sullivan, Director at Option Care Health (NASDAQ:OPCH), made a large insider sell on September 9, according to a new SEC filing.

OPCH

News

Majority Of US Senate Has Backed $770B National Defense Authorization Act, Voting Continues

By Benzinga Newsdesk

Today, 8:47 PM

-Reuters

SPY

Trump’s Social Media Venture Abruptly Loses Key Officials; Sparks Concerns

By Anusuya Lahiri

Today, 8:47 PM

Tech chief Josh Adams and product development chief Billy Boozer have resigned from former President Donald Trump’s ‘Truth…

AAPL

Verano Rolls Out New 5mg THC Edibles, BITS, Across 6 Markets

By Nina Zdinjak

Today, 8:47 PM

Multi-state cannabis company Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) is launching BITS - a new line of low-dose, high-function edibles that allow cannabis consumers to do more with less.

CSE:VRNO

Barclays Maintains Equal-Weight on Amdocs, Raises Price Target to $95

Related Posts

Notable Option Care Health Insider Makes $247.48 Million Sale

Majority Of US Senate Has Backed $770B National Defense Authorization Act, Voting Continues

Trump’s Social Media Venture Abruptly Loses Key Officials; Sparks Concerns

Verano Rolls Out New 5mg THC Edibles, BITS, Across 6 Markets